Basilea Pharmaceutica (BPMU.F) Stock Overview
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BPMU.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 68.95 |
| 52 Week High | CHF 72.14 |
| 52 Week Low | CHF 47.50 |
| Beta | 0.46 |
| 1 Month Change | 9.01% |
| 3 Month Change | 14.97% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | 15.88% |
| Change since IPO | 36.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| BPMU.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.5% | -0.4% |
| 1Y | n/a | 26.8% | 12.7% |
Return vs Industry: Insufficient data to determine how BPMU.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BPMU.F performed against the US Market.
Price Volatility
| BPMU.F volatility | |
|---|---|
| BPMU.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BPMU.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BPMU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 180 | David Veitch | www.basilea.com |
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections.
Basilea Pharmaceutica AG Fundamentals Summary
| BPMU.F fundamental statistics | |
|---|---|
| Market cap | US$850.73m |
| Earnings (TTM) | US$91.96m |
| Revenue (TTM) | US$298.96m |
Is BPMU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPMU.F income statement (TTM) | |
|---|---|
| Revenue | CHF 236.21m |
| Cost of Revenue | CHF 126.63m |
| Gross Profit | CHF 109.58m |
| Other Expenses | CHF 36.92m |
| Earnings | CHF 72.66m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Feb 17, 2026
| Earnings per share (EPS) | 5.91 |
| Gross Margin | 46.39% |
| Net Profit Margin | 30.76% |
| Debt/Equity Ratio | 79.5% |
How did BPMU.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 06:36 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Basilea Pharmaceutica AG is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |